Lancet Healthy Longev. 2025 Jun;6(6):100717. doi: 10.1016/j.lanhl.2025.100717. ABSTRACT BACKGROUND: Blood-based biomarkers (BBM) of neurodegenerative diseases are emerging as cost-effective tools in the differential diagnostics of Alzheimer’s disease and other dementias. Scarce data exist about factors explaining BBM variation in population-based cohorts, and their intergenerational associations are unknown. This study aimed…